Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.38B 8.2B 7.58B 7B 13.18B 901B 13.42B 90.35B 35.45B 441B 35.23B 34.45B 1,519B P/E 2026 *
-15.7x
P/E 2027 * -32.5x
Enterprise Value 9.13B 7.98B 7.37B 6.81B 12.83B 877B 13.06B 87.92B 34.5B 429B 34.28B 33.52B 1,478B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 6.58x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-2.56%
1 week-35.80%
Current month-30.10%
1 month-25.07%
3 months-27.80%
6 months-29.73%
Current year-29.95%
1 week 54.53
Extreme 54.53
86.74
1 month 54.53
Extreme 54.53
86.74
Current year 54.53
Extreme 54.53
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-2.52%-35.80%+30.25%+30.46% 9.38B
-1.05%+1.39%+3.15%+6.98% 50.61B
+0.38%-2.98%+381.57%+593.10% 39.11B
-0.01%-0.32%+29.62%-6.12% 34.64B
+0.86%-0.67%+21.72%+56.32% 33.79B
-1.31%-1.76%+1.59%+27.01% 26.89B
+0.62%-0.03% - - 16.47B
+1.38%-1.85%+67.38%+120.47% 15.14B
-0.72%+0.12%+14.69%+16.95% 13.85B
+1.56%-0.07%+12.76%-31.53% 12.72B
Average -0.07%-4.57%+62.53%+90.40% 25.26B
Weighted average by Cap. -0.09%-2.28%+78.58%+118.19%

Financials

2026 *2027 *
Net sales 889M 777M 718M 664M 1.25B 85.4B 1.27B 8.57B 3.36B 41.82B 3.34B 3.27B 144B 1.41B 1.23B 1.14B 1.05B 1.99B 136B 2.02B 13.61B 5.34B 66.44B 5.31B 5.19B 229B
Net income -594M -519M -480M -443M -835M -57.05B -850M -5.72B -2.24B -27.94B -2.23B -2.18B -96.19B -292M -255M -236M -218M -411M -28.07B -418M -2.82B -1.1B -13.74B -1.1B -1.07B -47.32B
Net Debt -252M -221M -204M -188M -355M -24.25B -361M -2.43B -954M -11.88B -948M -927M -40.89B -86.16M -75.29M -69.6M -64.31M -121M -8.28B -123M -830M -326M -4.05B -324M -316M -13.95B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-14 US$55.42 -2.35% 2,461,636
26-07-13 US$56.75 -2.58% 5,097,949
26-07-10 US$58.25 -9.37% 11,444,106
26-07-09 US$64.27 -23.90% 20,447,626
26-07-08 US$84.46 -2.17% 2,280,833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
56.75USD
Average target price
93.23USD
Spread / Average Target
+64.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock